Viridian Therapeutics, Inc. (VRDN) Stock

Viridian Therapeutics, Inc. (VRDN) is a Healthcare stock trading at $24.29 (as of 2026-08-21), with a market capitalization of $2.50B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Viridian Therapeutics, Inc. is a biotechnology company developing antibody-based therapies for serious diseases, including treatments targeting IGF-1R. Its pipeline includes VRDN-001 (humanized anti-IGF-1R) in a Phase 1/2 trial for thyroid eye disease, VRDN-002 in Phase 1, and VRDN-003 in Phase 1/2 for thyroid eye disease.

Understand Viridian Therapeutics, Inc.: how it makes money

Viridian Therapeutics develops monoclonal antibody treatments for serious diseases, including thyroid eye disease, and makes money through licensing and collaboration arrangements (as reflected in its License Revenue and Collaboration Revenue line items).

Because Viridian's main assets (VRDN-001, VRDN-002, VRDN-003) are in clinical trials, its profit model depends on future outcomes that can drive licensing and collaboration revenue, rather than on current sales of an approved, marketed product.

Revenue by segment (latest quarter)
License$0.0B
Collab$0.0B
Collab Rel$0.0B

Business quality (Weak): Latest reported quarter shows 0.0B revenue and a very large negative operating margin (operating_margin_pct of -82389.4), so investors are largely looking to clinical trial progress and potential future deal revenue rather than present cash earnings.

Bull case

  • Clinical outcomes appear stronger than placebo on key TED measures: Proptosis Responder Rate (Every Four Weeks) is 54% versus Proptosis Responder Rate (Placebo) of 18%, and Complete Diplopia Resolution Rate (Every Four Weeks) is 51% versus 16% for placebo.
  • Trial enrollment is underway, indicating active clinical execution: REVEAL-1 Patient Enrollment is 132 (Number of Patients Enrolled is 132), and REVEAL-2 Patient Enrollment is 204.

Bear case

  • No current revenue is shown in the latest quarter: For the quarter ended 2026-03-31, revenue_b is 0.0B, with License Revenue and Collaboration Revenue line items also at 0.0B.
  • Material loss profile to date: operating_margin_pct is -82389.4 in the latest reported quarter, reflecting a heavy operating deficit.
  • Clinical success is not guaranteed, and the company remains trial-stage: VRDN-001 is in Phase 1/2 for thyroid eye disease, and VRDN-002 and VRDN-003 are in Phase 1 clinical trials, so outcomes must improve to support future revenue opportunities.
Valuation — source: SEC EDGAR (first-party)
Price$24.29
Market Cap$2.50B
Price / Book3.94
Price / Sales35.33
FCF Yield-25.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$70.85M
Net Margin-483.6%
Revenue Growth (YoY)23359.9%
FCF Growth (YoY)18.9%
Financial Health — source: SEC EDGAR
Altman Z-Score6.16 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($300.82M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOStephen F. Mahoney
Employees143
CountryUS
IPO Date2014-06-18

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Rockwell Medical, Inc. (RMTI)
  • Lifecore Biomedical, Inc. (LFCR)
  • Aytu BioPharma, Inc. (AYTU)
  • CytomX Therapeutics, Inc. (CTMX)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Fortress Biotech, Inc. (FBIO)
  • Nuvation Bio Inc. (NUVB)
  • Eton Pharmaceuticals, Inc. (ETON)
VRDN earnings history · VRDN institutional & insider holders · VRDN KPIs & operating metrics · VRDN financials · VRDN investor presentations & press releases · VRDN SEC filings · VRDN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.